

# Maria A Hawkins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5587273/publications.pdf>

Version: 2024-02-01

190  
papers

4,200  
citations

136885

32  
h-index

123376

61  
g-index

195  
all docs

195  
docs citations

195  
times ranked

5270  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 657-664.	0.8	541
2	Stereotactic body radiotherapy for oligometastases. <i>Lancet Oncology</i> , The, 2013, 14, e28-e37.	5.1	436
3	Clinical development of new drug-radiotherapy combinations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 627-642.	12.5	230
4	Radiation therapy for hepatocellular carcinoma. <i>Cancer</i> , 2006, 106, 1653-1663.	2.0	221
5	Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 751-759.	0.4	195
6	UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. <i>Clinical Oncology</i> , 2018, 30, 5-14.	0.6	191
7	Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. <i>British Journal of Surgery</i> , 2013, 100, 1009-1014.	0.1	175
8	Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. <i>Lancet Oncology</i> , The, 2021, 22, 98-106.	5.1	147
9	Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 610-619.	0.4	108
10	The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 51-60.	0.4	75
11	Stereotactic Body Radiotherapy for Liver Metastases. <i>Clinical Oncology</i> , 2015, 27, 307-315.	0.6	51
12	Improving image-guided target localization through deformable registration. <i>Acta Oncologica</i> , 2008, 47, 1279-1285.	0.8	49
13	Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 849-857.	2.2	48
14	The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E164-E165.	0.4	46
15	ARCI: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016, 119, 306-311.	0.3	43
16	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 194-200.	0.3	43
17	Set-up errors in radiotherapy for oesophageal cancers - Is electronic portal imaging or conebeam more accurate?. <i>Radiotherapy and Oncology</i> , 2011, 98, 249-254.	0.3	39
18	Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1202-1211.	0.4	39

#	ARTICLE	IF	CITATIONS
19	Oesophagectomy after Definitive Chemoradiation in Patients with Locally Advanced Oesophageal Cancer. <i>Clinical Oncology</i> , 2008, 20, 221-226.	0.6	38
20	Anal Cancer: Developing an Intensity-modulated Radiotherapy Solution for ACT2 Fractionation. <i>Clinical Oncology</i> , 2014, 26, 720-721.	0.6	37
21	A tumor control probability model for anal squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2015, 116, 192-196.	0.3	37
22	Preclinical testing of an ATR inhibitor demonstrates improved response to standard therapies for esophageal cancer. <i>Radiotherapy and Oncology</i> , 2016, 121, 232-238.	0.3	37
23	NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2017, 74, 38-46.	1.3	37
24	Quantification of Organ Motion During Chemoradiotherapy of Rectal Cancer Using Cone-Beam Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e431-e438.	0.4	36
25	ESTRO ACROP guidelines for target volume definition in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021, 154, 60-69.	0.3	36
26	Organ-sparing Intensity-modulated Radiotherapy for Anal Cancer using the ACTII Schedule: A Comparison of Conventional and Intensity-modulated Radiotherapy Plans. <i>Clinical Oncology</i> , 2013, 25, 155-161.	0.6	35
27	Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015. <i>Clinical Oncology</i> , 2017, 29, 188-197.	0.6	35
28	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. <i>Oncotarget</i> , 2016, 7, 12672-12681.	0.8	34
29	Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review. <i>Radiotherapy and Oncology</i> , 2017, 125, 213-222.	0.3	34
30	The effect of treatment position, prone or supine, on dose-volume histograms for pelvic radiotherapy in patients with rectal cancer. <i>British Journal of Radiology</i> , 2009, 82, 321-327.	1.0	33
31	Radiobiological Determination of Dose Escalation and Normal Tissue Toxicity in Definitive Chemoradiation Therapy for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 423-429.	0.4	33
32	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 765-775.	3.7	33
33	Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization. <i>Frontiers in Oncology</i> , 2017, 7, 153.	1.3	32
34	Cone Beam Computed Tomography—Derived Adaptive Radiotherapy for Radical Treatment of Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 378-383.	0.4	30
35	Comparison of deliverable IMRT and VMAT for spine metastases using a simultaneous integrated boost. <i>British Journal of Radiology</i> , 2013, 86, 20120466.	1.0	29
36	NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. <i>BMC Cancer</i> , 2015, 15, 48.	1.1	29

#	ARTICLE	IF	CITATIONS
37	An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 199-207.	0.4	28
38	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. <i>European Journal of Cancer</i> , 2022, 164, 18-29.	1.3	27
39	Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy. <i>Clinical Oncology</i> , 2017, 29, 370-377.	0.6	25
40	UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes. <i>European Journal of Cancer</i> , 2020, 128, 7-16.	1.3	25
41	Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial. <i>BMC Cancer</i> , 2012, 12, 530.	1.1	24
42	Oesophageal Chemoradiotherapy in the UKâ€”Current Practice and Future Directions. <i>Clinical Oncology</i> , 2013, 25, 368-377.	0.6	24
43	Volumetric modulated arc therapy planning for distal oesophageal malignancies. <i>British Journal of Radiology</i> , 2012, 85, 44-52.	1.0	23
44	Doseâ€”intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study. <i>Cancer</i> , 2018, 124, 2001-2009.	2.0	23
45	Motion artifact correction in freeâ€”breathing abdominal MRI using overlapping partial samples to recover image deformations. <i>Magnetic Resonance in Medicine</i> , 2009, 62, 440-449.	1.9	22
46	Size Does Matter: Can we Reduce the Radiotherapy Field Size for Selected Cases of Anal Canal Cancer Undergoing Chemoradiation?. <i>Clinical Oncology</i> , 2009, 21, 376-379.	0.6	21
47	Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer. <i>Radiotherapy and Oncology</i> , 2015, 117, 246-251.	0.3	21
48	Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 729-737.	0.4	21
49	Proton Beam Therapy â€” the Challenges of Delivering High-quality Evidence of Clinical Benefit. <i>Clinical Oncology</i> , 2018, 30, 280-284.	0.6	21
50	HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. <i>Breast</i> , 2008, 17, 661-665.	0.9	20
51	Systematic review and meta-analysis of small bowel doseâ€”volume and acute toxicity in conventionally-fractionated rectal cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 138, 38-44.	0.3	20
52	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. <i>British Journal of Cancer</i> , 2020, 123, 709-713.	2.9	20
53	The Role of Radiotherapy and Chemoradiation in the Management of Primary Liver Tumours. <i>Clinical Oncology</i> , 2014, 26, 569-580.	0.6	19
54	Novel prostate brachytherapy technique: Improved dosimetric and clinical outcome. <i>Radiotherapy and Oncology</i> , 2008, 88, 121-126.	0.3	18

#	ARTICLE	IF	CITATIONS
55	Comparison of Acuros (AXB) and Anisotropic Analytical Algorithm (AAA) for dose calculation in treatment of oesophageal cancer: effects on modelling tumour control probability. <i>Radiation Oncology</i> , 2014, 9, 286.	1.2	18
56	Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study. <i>Radiotherapy and Oncology</i> , 2019, 141, 62-66.	0.3	18
57	Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data. <i>Radiotherapy and Oncology</i> , 2017, 123, 431-437.	0.3	17
58	The Application of Functional Imaging Techniques to Personalise Chemoradiotherapy in Upper Gastrointestinal Malignancies. <i>Clinical Oncology</i> , 2014, 26, 581-596.	0.6	16
59	Cone beam CT verification for oesophageal cancer – impact of volume selected for image registration. <i>Acta Oncologica</i> , 2011, 50, 1183-1190.	0.8	15
60	Challenges in using 18F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer. <i>Radiation Oncology</i> , 2014, 9, 146.	1.2	14
61	Early stage anal margin cancer: towards evidence-based management. <i>Colorectal Disease</i> , 2019, 21, 387-391.	0.7	14
62	The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 604387.	1.3	14
63	A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). <i>Radiation Oncology</i> , 2020, 15, 151.	1.2	14
64	Dynamic Shape Instantiation for Intra-operative Guidance. <i>Lecture Notes in Computer Science</i> , 2010, 13, 69-76.	1.0	14
65	Risk-adapted strategy partial liver irradiation for the treatment of large volume metastatic liver disease. <i>Acta Oncologica</i> , 2014, 53, 702-706.	0.8	13
66	A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the –SPARC– trial protocol. <i>BMC Cancer</i> , 2016, 16, 728.	1.1	13
67	Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer. <i>Radiotherapy and Oncology</i> , 2020, 143, 19-23.	0.3	13
68	A systematic review of health economic evaluations of proton beam therapy for adult cancer: Appraising methodology and quality. <i>Clinical and Translational Radiation Oncology</i> , 2020, 20, 19-26.	0.9	13
69	Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity. <i>Advances in Radiation Oncology</i> , 2020, 5, 1311-1319.	0.6	13
70	Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET). <i>Clinical Oncology</i> , 2017, 29, 707-710.	0.6	12
71	Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2016, 121, 86-91.	0.3	11
72	Driving developments in UK oesophageal radiotherapy through the SCOPE trials. <i>Radiation Oncology</i> , 2019, 14, 26.	1.2	11

#	ARTICLE	IF	CITATIONS
73	Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). <i>BMC Cancer</i> , 2019, 19, 121.	1.1	11
74	Chemoradiotherapy of locally-advanced non-small cell lung cancer: Analysis of radiation dose-response, chemotherapy and survival-limiting toxicity effects indicates a low $\hat{I}^2/\hat{I}^2$ ratio. <i>Radiotherapy and Oncology</i> , 2020, 143, 58-65.	0.3	11
75	Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 151, 280-286.	0.3	11
76	SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021, 155, 278-284.	0.3	11
77	214 A trial in design: CORE – Conventional Care or Radioablation in the treatment of Extracranial metastases. <i>Lung Cancer</i> , 2014, 83, S79.	0.9	10
78	Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer?. <i>Clinical Oncology</i> , 2019, 31, 72-80.	0.6	10
79	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. <i>Radiotherapy and Oncology</i> , 2021, 164, 104-114.	0.3	10
80	Intravenous contrast-enhanced cone beam computed tomography (IVCBCT) of intrahepatic tumors and vessels. <i>Advances in Radiation Oncology</i> , 2016, 1, 43-50.	0.6	9
81	Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 13, 24-30.	0.6	9
82	Respiratory Gated Cone-Beam CT Volumetric Imaging for External Beam Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, S27-S28.	0.4	8
83	Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>Clinical Oncology</i> , 2018, 30, 418-426.	0.6	8
84	Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. <i>European Journal of Cancer</i> , 2021, 153, 153-161.	1.3	8
85	Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT). <i>Radiotherapy and Oncology</i> , 2016, 121, 92-97.	0.3	7
86	A Randomised Trial of Conventional Care versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases. <i>Clinical Oncology</i> , 2018, 30, e64.	0.6	7
87	NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. <i>Cancer Genetics</i> , 2020, 248-249, 1-10.	0.2	7
88	NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch. <i>Antioxidants</i> , 2021, 10, 1380.	2.2	7
89	Unwrapping 3D complex hollow organs for spatial dose surface analysis. <i>Medical Physics</i> , 2016, 43, 6009-6016.	1.6	6
90	A Phase II trial of Higher Radiotherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial. <i>BMJ Open</i> , 2022, 12, e049119.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Challenges in implementing model-based phase I designs in a grant-funded clinical trials unit. <i>Trials</i> , 2017, 18, 620.	0.7	5
92	Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , 2021, 16, 95.	1.2	5
93	PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4166-TPS4166.	0.8	5
94	Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset. <i>Radiotherapy and Oncology</i> , 2021, 165, 119-125.	0.3	5
95	Feasibility of Free-breathing Respiratory Gated Liver Radiotherapy with MRI-derived Models. <i>Clinical Oncology</i> , 2007, 19, S13.	0.6	4
96	The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. <i>Radiation Oncology</i> , 2015, 10, 236.	1.2	4
97	The Challenge Facing Academic Radiotherapy Physics in the UK. <i>Clinical Oncology</i> , 2019, 31, 858-860.	0.6	4
98	Impact of abdominal compression on setup error and image matching during radical abdominal radiotherapy. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2019, 12, 28-33.	0.6	4
99	CTRad 10 Years On: From 10-point Plan to Top 10 Achievements. <i>Clinical Oncology</i> , 2020, 32, 9-12.	0.6	4
100	On-trial radiotherapy quality assurance in NeoSCOPE: A randomised phase II trial of chemoradiotherapy in oesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 119-119.	0.8	4
101	Patient and Public Involvement Refines the Design of ProtOeus: A Proposed Phase II Trial of Proton Beam Therapy in Oesophageal Cancer. <i>Patient</i> , 2021, 14, 545-553.	1.1	4
102	Comparison of Breath Hold Cone Beam CT and Orthogonal Image Guided Radiotherapy for Liver Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, S555-S556.	0.4	3
103	Cone beam CT verification for active breathing control (ABC)-gated radiotherapy for lung cancer. <i>Acta Oncologica</i> , 2014, 53, 716-719.	0.8	3
104	Stepwise Multicenter Introduction of Intensity Modulated Radiation Therapy for Anal Cancer in the United Kingdom: From Consensus Guidance to Large-Scale Prospective Audit, Prior to Future Clinical Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S105-S106.	0.4	3
105	Session 3: Beyond the boundaries of Total Mesorectal Excision - where surgeons fear to tread. <i>Colorectal Disease</i> , 2018, 20, 61-64.	0.7	3
106	Quantitative Analysis of Radiation-Associated Parenchymal Lung Change. <i>Cancers</i> , 2022, 14, 946.	1.7	3
107	Penile Bulb Dosimetry – Impact of Prostate Brachytherapy Implant Technique. <i>Clinical Oncology</i> , 2007, 19, S7-S8.	0.6	2
108	Locally Advanced Non-Metastatic Pancreatic Cancer – Can We Do More?. <i>Clinical Oncology</i> , 2008, 20, 532-534.	0.6	2



#	ARTICLE	IF	CITATIONS
109	Prospective Review of Outlining in the UK NeoSCOPE Esophageal Trial. International Journal of Radiation Oncology Biology Physics, 2014, 90, S733.	0.4	2
110	Oral Contrast Improves Soft Tissue Matching in Image Guided Radiation Therapy for Gastrointestinal (GI) Tumors. International Journal of Radiation Oncology Biology Physics, 2016, 96, E170-E171.	0.4	2
111	OC-0057: Cardiotoxicity and cardiac substructure dosimetry in doseescalated lung radiotherapy. Radiotherapy and Oncology, 2016, 119, S24-S25.	0.3	2
112	EP-1277: Optimising RT dose for anal cancer - the development of three clinical trials in one platform. Radiotherapy and Oncology, 2017, 123, S685-S686.	0.3	2
113	CORE: A randomised trial of COventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases. Lung Cancer, 2018, 115, S85-S86.	0.9	2
114	Patient and tumor characteristics impacting on lymph node metastases rate (LNMR) in squamous cell carcinoma of the anal canal and margin (SCCA) using data from the NCRI randomized phase III ACT II trial: Implications for radiotherapy target volume.. Journal of Clinical Oncology, 2014, 32, 4032-4032.	0.8	2
115	Image-guided radiotherapy for esophageal cancer. Imaging in Medicine, 2012, 4, 515-525.	0.0	2
116	228 Breath hold cone beam CT for image guided stereotactic radiotherapy for liver cancer. Radiotherapy and Oncology, 2006, 78, S80.	0.3	1
117	2639. International Journal of Radiation Oncology Biology Physics, 2006, 66, S566.	0.4	1
118	1072. International Journal of Radiation Oncology Biology Physics, 2006, 66, S170-S171.	0.4	1
119	VMAT Compared with Gated Highly Conformal Optimization for Dose Escalation in Partial Liver Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, S121-S122.	0.4	1
120	Nonsurgical Management of Esophageal Adenocarcinoma. Clinical Colorectal Cancer, 2011, 10, 165-170.	1.0	1
121	Organ Sparing IMRT for Anal Cancer using ACTII Schedule: a Comparison of Conventional and IMRT Plans. Clinical Oncology, 2011, 23, S31.	0.6	1
122	Normal tissue sparing with respiratory adapted volumetric modulated arc therapy for distal oesophageal and gastro-oesophageal tumours. Acta OncolÅ³gica, 2014, 53, 149-154.	0.8	1
123	KEAP1-NRF2 Pathway as a Modulator of Response to Radiation in Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e191-e192.	0.4	1
124	Analysis of On-trial Quality Assurance for the SPARC Clinical Trial using Novel Peer-review Methodology. Clinical Oncology, 2018, 30, e60.	0.6	1
125	NRF2 Metagene Expression Associated with Worse Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, S160.	0.4	1
126	Stereotactic radiotherapy and oligometastases â€œ Authors' reply. Lancet Oncology, The, 2021, 22, e133.	5.1	1



#	ARTICLE	IF	CITATIONS
127	NeoSCOPE: A phase II randomized comparison of neoadjuvant oxaliplatin/capecitabine versus carboplatin/paclitaxel-based chemoradiation in operable esophageal cancer.. Journal of Clinical Oncology, 2014, 32, TPS4144-TPS4144.	0.8	1
128	NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 3-3.	0.8	1
129	Salvage surgery with abdominoperineal excision of the rectum (APER) following loco-regional failure after chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA) and the impact on long-term outcomes: Results of ACT II.. Journal of Clinical Oncology, 2016, 34, 3523-3523.	0.8	1
130	Imaging Response Assessment Using Finite Element Model-Based Deformable Image Registration: Application to Liver Disease. International Journal of Radiation Oncology Biology Physics, 2005, 63, S140-S141.	0.4	0
131	To Determine the Volume of Bowel and Dose Received in the Pelvic Radiation Field for Rectal Cancer in the Prone and Supine Position. International Journal of Radiation Oncology Biology Physics, 2005, 63, S165.	0.4	0
132	Case 23-2005: A Man with a Mass in the Liver. New England Journal of Medicine, 2005, 353, 2195-2197.	13.9	0
133	102 MV, kV, and 3D image guidance for high precision liver cancer radiotherapy. Radiotherapy and Oncology, 2005, 76, S31.	0.3	0
134	60 Improving image-guided target localization through deformable registration. Radiotherapy and Oncology, 2006, 80, S18.	0.3	0
135	3531 POSTER Toxicity and outcomes of chemoradiation without elective nodal irradiation after chemotherapy for unresectable pancreatic cancer. European Journal of Cancer, Supplement, 2007, 5, 268-269.	2.2	0
136	QUANTIFICATION OF ORGAN MOTION DURING CHEMO-RADIATION OF RECTAL CANCER USING CONE BEAM CT (MEASURE STUDY). Radiotherapy and Oncology, 2009, 92, S182.	0.3	0
137	IMAGE REGISTRATION USING 6 VERSUS 4 DEGREES OF FREEDOM FOR VERIFICATION OF RADICAL PROSTATE RADIOTHERAPY. Radiotherapy and Oncology, 2009, 92, S186.	0.3	0
138	VMAT PLANNING AND DELIVERY FOR DISTAL OESOPHAGEAL MALIGNANCIES. Radiotherapy and Oncology, 2009, 92, S197.	0.3	0
139	Highly Conformal Partial Liver Irradiation for Chemorefractory Unresectable Colorectal Liver Metastases. International Journal of Radiation Oncology Biology Physics, 2010, 78, S327-S328.	0.4	0
140	1303 poster INTENSITY MODULATED RADIOTHERAPY (IMRT) SOLUTIONS FOR ANAL CANCER TREATMENT USING UK ACT-II SCHEDULE. Radiotherapy and Oncology, 2011, 99, S488.	0.3	0
141	449 poster INDIVIDUALISING STEREOTACTIC LIVER RADIOTHERAPY FOR LARGE TUMOUR VOLUMES USING LIVER NORMAL TISSUE COMPLICATION PROBABILITY (NTCP) ESTIMATION. Radiotherapy and Oncology, 2011, 99, S181.	0.3	0
142	1334 poster VOLUMETRIC MODULATED ARC RADIOTHERAPY (VMAT) OF TUMOURS IN THE THORAX â€œ ACUTE TOXICITY RESULTS FROM A SINGLE CENTRE. Radiotherapy and Oncology, 2011, 99, S499.	0.3	0
143	Evaluation of Respiratory-adapted Volumetric Modulated Arc Radiotherapy (VMAT) Planning for Gastro-esophageal Malignancies. International Journal of Radiation Oncology Biology Physics, 2011, 81, S323-S324.	0.4	0
144	Effect of Anaemia Prevention on Survival and Local Control in Oesophageal Cancers Treated with Chemoradiotherapy. Clinical Oncology, 2012, 24, 454-455.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Evaluating Small Bowel Doseâ€“Volume Tolerance Limits for SBRT Using a Preoperative Rectal Radiation Therapy Model: Are We Setting the Bar Too High?. International Journal of Radiation Oncology Biology Physics, 2013, 87, S54.	0.4	0
146	Impact of Weight Change on Dose Delivery in Pancreatic Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, S862-S863.	0.4	0
147	A Tumor Control Probability Model for Anal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, S399-S400.	0.4	0
148	P-182 Clinical outcomes of a phase II study of nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy in locally-advanced pancreatic cancer â€“ functional imaging is prognostic and provides proof of mechanism. Annals of Oncology, 2015, 26, iv53.	0.6	0
149	The Application of Pre and Post Chemoradiation Therapy FDG-PET/CT to Treatment Strategy Selection in Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, E130-E131.	0.4	0
150	PV-0171: Can protons reduce bone marrow toxicity in definitive chemoradiotherapy for oesophageal tumours?. Radiotherapy and Oncology, 2016, 119, S81.	0.3	0
151	PO-0713: Conformity analysis of target-volume definition for margin-directed boost in pancreatic cancer SBRT. Radiotherapy and Oncology, 2016, 119, S333-S334.	0.3	0
152	EP-1721: Feature extraction from duodenal dose surface maps to predict toxicity in pancreatic chemoradiation. Radiotherapy and Oncology, 2016, 119, S805.	0.3	0
153	EP-1720: Impact of contouring variability on tumour control and normal tissue toxicity in liver SBRT. Radiotherapy and Oncology, 2016, 119, S804-S805.	0.3	0
154	EP-1937: UK stereotactic ablative radiotherapy trials normal tissue dose constraints tolerance consensus. Radiotherapy and Oncology, 2016, 119, S919.	0.3	0
155	EP-1268: Dosimetric parameters predict toxicity in chemoradiotherapy with nelfinavir for pancreatic cancer. Radiotherapy and Oncology, 2016, 119, S597-S598.	0.3	0
156	EP-1941: Assessment of variation in planning benchmark case for ABC-07 trial of liver SBRT. Radiotherapy and Oncology, 2016, 119, S921.	0.3	0
157	Four-dimensional Computed Tomography Contouring Variability in Stereotactic Body Radiotherapy of Non-resectable Biliary Tract Cancer. Clinical Oncology, 2017, 29, e137.	0.6	0
158	Stomach Dose-Volume Parameters and Clinical Factors Predict Acute Toxicity in Pancreatic Cancer Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, E155.	0.4	0
159	A Novel Pretrial Contouring Exercise for the UK led Personalising Anal cancer radioTherapy dOse (PLATO) Trial. International Journal of Radiation Oncology Biology Physics, 2017, 99, E181-E182.	0.4	0
160	Clinical and Dosimetric Factors Impacting Radiation Pneumonitis in Isotoxically Dose-Escalated NSCLC. International Journal of Radiation Oncology Biology Physics, 2017, 99, S153.	0.4	0
161	EP-1626: Predicting motion of normal tissue using incomplete real-time data during lung radiotherapy. Radiotherapy and Oncology, 2017, 123, S880-S881.	0.3	0
162	EP-1425: Permit to enter no-fly-zone: Risk-adapted mediastinal SBRT for oligometastases safe and effective. Radiotherapy and Oncology, 2017, 123, S761.	0.3	0

#	ARTICLE	IF	CITATIONS
163	EP-1732: Treatment planning of dose escalation for anal cancer in the PLATO trial. <i>Radiotherapy and Oncology</i> , 2017, 123, S952-S953.	0.3	0
164	Changes in Pelvic Active Bone Marrow seen on FDG-PET in Patients Receiving Concurrent Chemoradiation for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e17.	0.4	0
165	Are All Colorectal Oligometastases Equal?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e14.	0.4	0
166	Interfraction Duodenal Dose-Surface Map Changes with and without Abdominal Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e560.	0.4	0
167	PV-0475: Stereotactic Body Radiation Therapy For Painful Spinal Metastases - Results Of A Phase 2 Study. <i>Radiotherapy and Oncology</i> , 2018, 127, S244.	0.3	0
168	PO-0747: Validation of the survival model including cardiac substructure dosimetry in NSCLC. <i>Radiotherapy and Oncology</i> , 2018, 127, S383-S384.	0.3	0
169	PO-0769: NeoSCOPE RTTQA: pre-accrual and on-trial review of all patients in a UK oesophageal RT trial. <i>Radiotherapy and Oncology</i> , 2018, 127, S397.	0.3	0
170	PO-1080: 4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial?. <i>Radiotherapy and Oncology</i> , 2018, 127, S608.	0.3	0
171	Session 3: Intraoperative radiotherapy – creating new surgical boundaries. <i>Colorectal Disease</i> , 2018, 20, 65-75.	0.7	0
172	EP-1461 SBRT Pelvic re-irradiation: 2cm "rind" around PTV and small bowel dosimetry of rectal recurrences. <i>Radiotherapy and Oncology</i> , 2019, 133, S792.	0.3	0
173	PO-1121 Characterizing Dosimetric Uncertainties to Tumour Volume and Organs at Risk in Rectal Cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S622-S623.	0.3	0
174	PV-0625 Biological factors influencing outcomes in SBRT for colorectal cancer oligometastases (OM). <i>Radiotherapy and Oncology</i> , 2019, 133, S332-S333.	0.3	0
175	Reply to Comment on –The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic–. <i>British Journal of Cancer</i> , 2021, 124, 679-680.	2.9	0
176	A decision tool for radiographer-led abdominal image-guided stereotactic ablative body radiotherapy – Experience from a single institution. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2021, 19, 33-36.	0.6	0
177	SU-FF-J-78: Evaluation of Setup Accuracy for Hypofractionated Radiotherapy of Liver Using Portal Imaging and On-Line KV Fluoroscopy. <i>Medical Physics</i> , 2005, 32, 1937-1938.	1.6	0
178	A multicenter randomized phase II study of UFT/leucovorin and radiotherapy (RT) with or without cetuximab following induction gemcitabine plus capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2010, 28, TPS221-TPS221.	0.8	0
179	Does phase I radiotherapy dose of 30.6Gy in 17 fractions provide adequate microscopic nodal disease control in squamous cell carcinoma of the anus?. <i>Journal of Clinical Oncology</i> , 2012, 30, 588-588.	0.8	0
180	SU-E-T-606: Forward Planned Fluence-Painted Reduced Fields with Tangential Parent Beams for Total Breast Irradiation. <i>Medical Physics</i> , 2013, 40, 345-345.	1.6	0

#	ARTICLE	IF	CITATIONS
181	MO-F-WAB-01: A Comparison of 20 Free Breathing Versus AlignRT Based DIBH Breast Treatments. Medical Physics, 2013, 40, 409-410.	1.6	0
182	Volumetric analysis of anal cancer relapses following radical chemoradiation.. Journal of Clinical Oncology, 2014, 32, 576-576.	0.8	0
183	ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)â€Mechanism and clinical outcomes.. Journal of Clinical Oncology, 2015, 33, e15279-e15279.	0.8	0
184	THâ€ABâ€BRBâ€1: A Method of Unwrapping 3D Complex Hollow Organs for Spatial Dose Surface Analysis. Medical Physics, 2015, 42, 3706-3706.	1.6	0
185	SUâ€Eâ€Tâ€69: A Radiobiological Investigation of Dose Escalation in Lower Oesophageal Tumours with a Focus On Gastric Toxicity. Medical Physics, 2015, 42, 3346-3347.	1.6	0
186	WE-AB-202-10: Modelling Individual Tumor-Specific Control Probability for Hypoxia in Rectal Cancer. Medical Physics, 2016, 43, 3796-3796.	1.6	0
187	SU-D-BRA-06: Duodenal Interfraction Motion with Abdominal Compression. Medical Physics, 2016, 43, 3340-3340.	1.6	0
188	SPARC: A phase-I trial of pre-operative margin-intensified stereotactic radiotherapy for pancreatic cancer at high risk of positive resection margins.. Journal of Clinical Oncology, 2018, 36, TPS536-TPS536.	0.8	0
189	Outcomes following stereotactic body radiotherapy (SBRT) in locally recurrent rectal cancer (LRRC) in a previously irradiated pelvis.. Journal of Clinical Oncology, 2019, 37, 640-640.	0.8	0
190	Nrf2 metagene as a prognostic biomarker across all stages of colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, 557-557.	0.8	0